Global Regulatory Update – Full SpotlightPublished: June 27, 2019
GUEST EDITOR: Dr Christiane Niederlaender, Senior Quality Assessor, Biologicals, MHRA
The past few years have witnessed an unprecedented increase in the range of expedited regulatory pathways potentially available to cell & gene therapy developers across the world. From RMAT to PRIME, and from Breakthrough Designation to the PMD Act, a weight of experience and insight now exists to help you capitalize on the benefits whilst avoiding the pitfalls.
You can download the full Spotlight on Global Regulatory Update free of charge – simply login or register here to become a member